This series on “The Use of Advanced Cardiac MRI in Heart Failure and Cardiac Hypertrophy” is edited by Andrew J. M. Lewis and Oliver J. Rider from Radcliffe Department of Medicine, University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), University of Oxford, Oxford, UK.
Cardiovascular magnetic resonance (CMR) provides an exquisite anatomical and functional assessment of the heart and vascular system and does so without the use of ionizing radiation. Through the development of an array of specialised and complementary imaging sequences, clinical CMR has now become a “one-stop shop” for diagnostic and prognostic imaging to answer a wide range of clinical questions.
Cardiovascular magnetic resonance: at the heart of 21st Century imaging
Should everyone have an MRI in heart failure?
Should CMR be the default imaging modality in clinical trials for heart failure?
Obesity-related ventricular remodelling is exacerbated in dilated and hypertrophic cardiomyopathy
The use of cardiovascular magnetic resonance for the assessment of left ventricular hypertrophy
Use of cardiac magnetic resonance to detect changes in metabolism in heart failure
Cardiovascular magnetic resonance imaging for inflammatory heart diseases
The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology
Non-invasive investigation of myocardial energetics in cardiac disease using 31P magnetic resonance spectroscopy
Disclosure:
The series “The Use of Advanced Cardiac MRI in Heart Failure and Cardiac Hypertrophy” was commissioned by the editorial office, Cardiovascular Diagnosis and Therapy without any sponsorship or funding. Andrew J. M. Lewis and Oliver J. Rider served as the unpaid Guest Editors for the series.